

File reference	W17Fol476
Key words	Biologics & biosimilar prescribing
Date of release	22/09/2017
Attachments	No

Freedom of Information Act Disclosure log - Reply Extract

You asked

Regarding biologics and biosimilar prescribing. Could you please provide me with the following numbers of patients treated in the last 12 months [latest 12 months possible] with the following drugs for the either dermatology or gastroenterology departments.

Number of patients treated	Dermatolog y	Gastroenterolog y
TOTAL	192	238
Abatacept [Orencia]	0	0
Adalimumab [Humira]	38	135
Apremilast [Otezla]	57	0
Baricitinib [Olumiant]	0	0
Certolizumab [Cimzia]	0	0
Etanercept [Enbrel]	6	0
Etanercept Biosimilar [Benepali or Erelzi]	15	0
Golimumab [Simponi]	0	8
Infliximab [Remicade]	5 or fewer	5 or fewer
Infliximab Biosimilar [Inflectra, Remsima or Flixabi]	6	61
Rituximab [Mabthera]	0	0
Rituximab Biosimilar [Rixathon or Truxima]	0	0
Secukinumab [Cosentyx]	25	0
Tocilizumab [Ro Actemra]	0	0
Tofacitinib [Xeljanz]	0	0
Ustekinumab [Stelara]	44	5 or fewer
Vedolizumab [Entyvio]	0	29
Ixekizumab [Taltz]	0	0

Attachments included: No